Irving Weissman Net Worth

The estimated Net Worth of Irving Weissman is at least $17.3 Million dollars as of 26 April 2019. Irving Weissman owns over 20,000 units of Forty Seven stock worth over $15,498,346 and over the last few years he sold FTSV stock worth over $1,685,999. In addition, he makes $135,341 as Independent Director at Forty Seven.

Irving Weissman FTSV stock SEC Form 4 insider trading

Irving has made over 10 trades of the Forty Seven stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of FTSV stock worth $367,000 on 26 April 2019.

The largest trade he’s ever made was selling 26,384 units of Forty Seven stock on 25 February 2019 worth over $448,000. On average, Irving trades about 10,000 units every 12 days since 2018. As of 26 April 2019 he still owns at least 2,052,761 units of Forty Seven stock.

You can see the complete history of Irving Weissman stock trades at the bottom of the page.

Irving Weissman biography

Dr. Irving L. Weissman is Independent Director of the Company. Since 2003, Dr. Weissman has served as the Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research. Dr. Weissman was a member of the founding Scientific Advisory Boards of Amgen, a biotechnology company, and T Cell Sciences, Inc., a biotechnology company. He also previously served as a member of the board of directors of StemCells, Inc., acquired by Microbot Medical Ltd. in 2016, a pharmaceutical company, from 1997 to 2016. He co-founded, served as a Director, and chaired the Scientific Advisory Board at SyStemix, Inc., a biotechnology company, StemCells, Inc., a biotechnology company, and Cellerant Therapeutics, Inc., a biotechnology company. Dr. Weissman is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Association of Arts and Sciences. He received a B.S. from Montana State University and an M.D. from Stanford University School of Medicine. He has several honorary Ph.D.s.

How old is Irving Weissman?

Irving Weissman is 78, he’s been the Independent Director of Forty Seven since 2015. There are no older and 9 younger executives at Forty Seven.

What’s Irving Weissman’s mailing address?

Irving’s mailing address filed with the SEC is C/O FORTY SEVEN, INC., 1490 O’BRIEN DRIVE, SUITE A, MENLO PARK, CA, 94025.

Insider trading at Forty Seven

Over the last few years, insiders at Forty Seven have traded over $4,118,522 worth of Forty Seven stock and bought 2,621,245 units worth $41,666,515 . The most active insider traders include Tench Coxe, Michael L Speiser, and Jeffrey W Bird. On average, Forty Seven executives and independent directors trade stock every 7 days with the average trade being worth of $569,591. The most recent stock trade was executed by Mark Anthony Mc Camish on 20 May 2019, trading 16,500 units of FTSV stock currently worth $80,520.

What does Forty Seven do?

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

What does Forty Seven’s logo look like?

Complete history of Irving Weissman stock trades at Forty Seven

Forty Seven executives and stock owners

Forty Seven executives and other stock owners filed with the SEC include:

  • Mark McCamish, President, Chief Executive Officer, Director
  • Ann Rhoads, Chief Financial Officer
  • Chris Takimoto, Chief Medical Officer
  • Ian Clark, Independent Director
  • Craig Gibbs, Chief Business Officer
  • Kristine Ball, Independent Director
  • Jeffrey Bird, Lead Independent Director
  • Dennis Henner, Independent Director
  • Ravindra Majeti, Independent Director
  • Irving Weissman, Independent Director
  • Samuel J Iii Pullara,
  • Harbor Master Investors (Ca…, 10% owner
  • Michael L Speiser, 10% owner
  • Stefan A Dyckerhoff,
  • Venture Partners X, L.P.Lig…,
  • Hill Ventures Sutter,
  • Peter Nieh, 10% owner
  • Christopher J Schaepe, Director
  • Tench Coxe, 10% owner
  • Dennis Henner, Director
  • James N White, 10% owner
  • Venture Partners Select Ii,…,
  • Ravi Mhatre, 10% owner